Concarlo awarded patent for novel therapeutic peptide for drug-resistant breast cancer
Concarlo Holdings has received a US patent for IpY, a novel therapeutic peptide that addresses drug-resistant breast cancer by targeting a unique cellular pathway — p27Kip1. The patent is the latest step in Concarlo’s journey to commercialize revolutionary medicines for metastatic breast cancer. Concarlo has also announced that a new provisional patent application has been […]
